{
    "eid": "2-s2.0-85138022363",
    "title": "Activating Mutation in the Receptor Tyrosine Kinase FLT3 with Clinicopathological Relevance in Canine Mast Cell Tumors",
    "cover-date": "2022-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Veterinary (all)",
            "@code": "3400",
            "@abbrev": "VETE"
        }
    ],
    "keywords": [],
    "authors": [
        "Nawin Manachai",
        "Kasem Rattanapinyopituk",
        "Piyanoot Fonghem",
        "Panrawee Phoomvuthisarn",
        "Shingo Nakahata",
        "Kazuhiro Morishita",
        "Anudep Rungsipipat"
    ],
    "citedby-count": 1,
    "ref-count": 51,
    "ref-list": [
        "Mechanisms of receptor tyrosine kinase activation in cancer",
        "Cell signaling by receptor tyrosine kinases",
        "Stem cell factor receptor/c-Kit: from basic science to clinical implications",
        "Prevalence of KIT expression in human tumors",
        "Somatic activation of KIT in distinct subtypes of melanoma",
        "Assessment of canine mast cell tumor mortality risk based on clinical, histologic, immunohistochemical and molecular features",
        "Mutational hotspot of TET2, IDH1, IDH2, SRSF2, SF3B1, KRAS, and NRAS from human systemic mastocytosis are not conserved in canine mast cell tumors",
        "Canine mast cell tumours: a review of the pathogenesis, clinical features, pathology and treatment",
        "A point mutation in the extracellular domain of KIT promotes tumorigenesis of mast cells via ligand-independent auto-dimerization",
        "Current treatment options in patients with mastocytosis: status in 2015 and future perspectives",
        "Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors",
        "The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis",
        "Masitinib is safe and effective for the treatment of canine mast cell tumors",
        "Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision",
        "Tyrosine kinase inhibitors in veterinary medicine",
        "Rheostatic functions of mast cells in the control of innate and adaptive immune responses",
        "Identification of mast cell progenitors in adult mice",
        "Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis",
        "The roles of FLT3 in hematopoiesis and leukemia",
        "Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3",
        "Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia",
        "FLT3/D835Y mutation knock-in mice displayless aggressive disease compared with FLT3/internal tandem duplication (ITD) mice",
        "FLT3: ITDoes matter in leukemia",
        "The role of FLT3 in haematopoietic malignancies",
        "Targeting FLT3 mutations in AML: review of current knowledge and evidence",
        "Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease",
        "Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior",
        "RAS, FLT3, and C-KIT mutations in immunophenotyped canine leukemias",
        "Loss of NDRG2 expression activates PI3K-AKT signaling via PTEN phosphorylation in ATLL and other cancers",
        "AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations",
        "Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines",
        "Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes",
        "Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell",
        "Chronic myelogenous leukemia stem cells: what's new?",
        "Identification of a leukemia-initiating stem cell in human mast cell leukemiacation of a leukemia-initiating stem cell in human mast cell leukemia",
        "Identification of Flt3 lympho-myeloid stem cells lacking erythro-megakaryocytic potential: a revised road map for adult blood lineage commitment",
        "FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia",
        "An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment",
        "FLT3 mutations in canine acute lymphocytic leukemia",
        "Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML)",
        "Prognosis and outcome of patients with acute myeloid leukemia based on FLT3-ITD mutation with or without additional abnormal cytogenetics",
        "PML/RAR alpha and FLT3-ITD induce an APL-like disease in a mouse model",
        "Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol",
        "Acute myeloid leukemia diagnosis in the 21st century",
        "Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model",
        "European consensus document on mast cell tumours in dogs and cats",
        "Use of neutrophil to lymphocyte ratio for predicting histopathological grade of canine mast cell tumours",
        "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia",
        "Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain",
        "Midostaurin approved for FLT3-mutated AML",
        "Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Miyazaki",
            "@id": "60015659",
            "affilname": "University of Miyazaki Faculty of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015659",
            "affiliation-country": "Japan"
        },
        {
            "affiliation-city": "Chaing Mai",
            "@id": "60000881",
            "affilname": "Chiang Mai University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60000881",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": []
}